Nanotechnology-Based Cancer Vaccine
Nanotechnology offers invaluable tools to tailor cancer vaccines in order to generate robust antitumor immune response. Among the types of vehicles for cancer vaccines, nanoparticles (NPs) are easier to produce with better scalability. Several nanostructures have been discussed in literature as potential delivery systems for cancer antigens. Here, we focus on polymeric NPs fabricated from poly(d,l-lactic-co-glycolic) acid (PLGA). We describe how to prepare and characterize such NPs loaded with ovalbumin (OVA) antigen and immune adjuvant monophosphoryl lipid A (MPLA). We further describe methods to test the immune efficacy of such NPs in vitro and in vivo.
Key wordsCancer vaccine Nanoparticle (NPs) Poly(d,l-lactic-co-glycolic) acid (PLGA) Immunotherapy Dendritic cell (DC)
This work was supported by King Abdullah Institute for Nanotechnology and the Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia.
- 2.Hamdy S, Alshamsan A, Samuel J (2009) Nanotechnology for cancer vaccine delivery, Nanotechnology in drug delivery. Springer, New York, pp 519–543Google Scholar
- 10.Hamdy S, Elamanchili P, Alshamsan A, Molavi O, Satou T, Samuel J (2007) Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D, L-lactic-co-glycolic acid) nanoparticles. J Biomed Mater Res A 81(3):652–662. doi: 10.1002/jbm.a.31019 CrossRefPubMedGoogle Scholar
- 11.Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, Elhasi S, Samuel J, Lavasanifar A (2008) Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 26(39):5046–5057. doi: 10.1016/j.vaccine.2008.07.035 CrossRefPubMedGoogle Scholar
- 15.Riss TL, Moravec RA, Niles AL, Benink HA, Worzella TJ, Minor L (2004) Cell viability assays. In: Sittampalam GS, Coussens NP, Nelson H et al (eds) Assay guidance manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda, MDGoogle Scholar